26 results about "Ketoglutaric Acid" patented technology

The present disclosure provides a method for promoting in vitro development of mammalian embryos, comprising the step of adding alpha-ketoglutarate in the embryo development fluid at 90-180h after in vitro fertilization. Compared with the method of adding throughout the whole embryo development, the present disclosure finds that the promotion of embryo development efficiency is more significant when alpha-ketoglutarate is added after 90 hours after fertilization (90 hours to 180 hours after fertilization).

The present application relates to the technical field of feeding of crucian carp, and discloses a compound functional feed for repairing carbonate alkali damage of crucian carp, which is composed of alpha-ketoglutaric acid, linoleic acid, laurylene and basic feed, wherein the weight ratio of the alpha-ketoglutaric acid accounts for 1.5% of the total weight of the compound functional feed for repairing carbonate alkali damage of crucian carp, and the weight ratio of the linoleic acid accounts for 0.7% of the total weight of the compound functional feed for repairing carbonate alkali damage of crucian carp. The compound functional feed for repairing carbonate alkali damage of crucian carp can significantly enhance the repair capacity of the tissue cells of the crucian carp, improve the disease resistance of the crucian carp, reduce the risk of diseases and promote the energy metabolism process of the crucian carp, so as to ensure the efficient use of energy and maintain the normal homeostasis of the body.

The application discloses a genetically engineered bacterium for efficiently producing itaconic acid by using corn stalk hydrolysate and application thereof, and belongs to the technical field of gene recombination and metabolic engineering. The genetically engineered bacterium for efficiently producing itaconic acid by using corn stalk hydrolysate is characterized by the following aspects: taking a strain BW08 as a starting strain, heterologously expressing a homocentric acid decarboxylase gene CAD, deleting an isocitric acid dehydrogenase gene Icd, heterologously expressing a xylose acid dehydrase gene XD, a 2-keto-3-deoxy-xylose acid dehydrase gene KDXD and an alpha-ketoglutaric acid semialdehyde dehydrogenase gene KGSADH, and heterologously expressing a citric acid synthase gene gltA. In the fed-batch fermentation, the yield of itaconic acid of the genetically engineered bacterium reaches 68.6 g / L, and the conversion rate reaches 0.6 g / g (total sugar). The genetically engineered bacterium can efficiently metabolize corn stalk hydrolysate to produce itaconic acid.

The present disclosure provides a SNP molecular marker related to the alpha-ketoglutaric acid trait of dairy cows and application thereof. The SNP molecular marker is selected from one or more SNP loci shown in Table 14. The SNP molecular marker and the advantageous genotype provided by the present disclosure are of great significance for the assisted identification and early screening of dairy cows with the excellent trait of high alpha-ketoglutaric acid content.

This invention belongs to the field of molecular biology technology, specifically involving tRF5-22-SeCTCA-1, tRF5-22-SeCTCA-1 detection reagents, kits, and their applications. This invention discovers and verifies that tRF5-22-SeCTCA-1 plays a key regulatory role in the process of 5-fluorouracil (5-FU) chemotherapy resistance in colorectal cancer, filling a gap in the research of tRNA-derived fragments (tRFs) in colorectal cancer chemotherapy resistance. It is the first tRF molecule reported to be associated with 5-FU chemotherapy resistance in colorectal cancer, providing a novel molecular target and research direction for predicting chemotherapy resistance in colorectal cancer. This invention also provides a therapeutic strategy targeting tRF5-22-SeCTCA-1 and establishes α-ketoglutarate as an independent reversal agent, providing multi-dimensional technical solutions for the precision diagnosis and treatment of colorectal cancer and the reversal of chemotherapy resistance.

The application discloses application of bio-organic acid in preparation of plasmid conjugation transfer inhibitor and / or antibacterial drugs. The bio-organic acid in the application includes one or more of citric acid, fumaric acid or alpha-ketoglutaric acid. The application finds the possibility of the bio-organic acid as the conjugation transfer inhibitor in preventing and controlling the spread of antibiotic resistance level through in-vivo and in-vitro conjugation tests. The application provides the use of the bio-organic acid as the conjugation transfer inhibitor, limits the conjugation transfer of various clinical drug-resistant plasmids, and is one of strategies for solving the problem of bacterial drug resistance.

The application discloses genetically engineered bacteria for producing alpha-ketoglutaric acid and application. The genetically engineered bacteria are obtained by weakening the expression of alpha-ketoglutaric acid dehydrogenase gene odhA, weakening the expression of glutamate transporter protein gene cg1434, weakening the expression of glutamate synthase key subunit gene gltB, weakening the expression of lactic acid dehydrogenase gene ldh, weakening the expression of glutamate dehydrogenase gene gdh, weakening the expression of serine / threonine protein kinase gene pknG, enhancing the expression of pyruvate carboxylase gene pyc, introducing and expressing glutamate oxidase gene lgox at the site of lactic acid dehydrogenase ldh gene, and enhancing the expression of strong catalase gene katA on the basis of a Corynebacterium glutamicum starting strain. The genetically engineered bacteria can efficiently produce alpha-ketoglutaric acid under the condition of limited ammonia culture, and have a good application prospect.

This invention belongs to the field of biomedical technology, and specifically relates to a nutrient composition for the prevention and / or treatment of post-traumatic stress disorder (PTSD). This invention utilizes metabolomics technology to screen and identify metabolite changes occurring during the pathophysiological process of PTSD, and then designs a nutrient composition comprising five components: α-ketoglutarate, thiamine hydrochloride, L-serine, L-tryptophan, and L-tyrosine. Combined supplementation of these five nutrient components effectively improves anxiety-like behavior and promotes the extinction of fear memories in PTSD model mice. Furthermore, the nutrient composition of this invention exhibits extremely high safety, with side effects far lower than traditional chemically synthesized drugs, and is expected to improve long-term patient adherence.

The application provides a method for enhancing the expansion and activation of memory-like NK cells, and belongs to the technical field of cell culture. The application provides a method for obtaining strong memory-like NK cells, which comprises using complete culture medium, IL-2, IL-12, IL-15, IL-18, sodium alpha-ketoglutarate and DOT1L inhibitor; the concentration of the sodium alpha-ketoglutarate is 0.1-2 mM, and the concentration of the DOT1L inhibitor is 10-100 nM. The addition of low-concentration sodium alpha-ketoglutarate in the complete culture medium of memory-like NK cells can promote the in-vivo and in-vitro proliferation capacity of the memory-like NK cells. The addition of low-concentration DOT1L inhibitor in the late culture stage can further enhance the killing function of the memory-like NK cells by inhibiting H3K79me2 / 3, etc., so that memory-like NK cells with a larger number and stronger killing capacity are obtained.

The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

This invention discloses the application of α-ketoglutarate in the preparation of agents that promote oligodendrocyte precursor cell differentiation, belonging to the field of biomedical technology. This invention is the first to use α-ketoglutarate in the preparation of drugs for the prevention and / or treatment of OPC differentiation disorders. Experimental results show that exogenous supplementation with α-ketoglutarate or its derivatives can regulate the differentiation level of OPCs under physiological conditions, effectively promote OPC differentiation, and improve symptoms such as decreased motor function and shortened lifespan caused by OPC differentiation defects. It demonstrates good efficacy and safety, and possesses high clinical application value.

This invention discloses a brewer's yeast fermentation product solution and its application in cosmetics. The brewer's yeast fermentation product solution is prepared using modern fermentation technology, employing soybean milk, buckwheat sprouts, rice bran, algae, etc., as a composite fermentation substrate. Utilizing the metabolic activity of ordinary yeast, combined with subsequent yeast autolysis / enzymatic hydrolysis, a brewer's yeast fermentation product solution rich in α-ketoglutarate, polysaccharides, oligosaccharides, free amino acids, polypeptides, and B vitamins is prepared. This brewer's yeast fermentation product solution possesses moisturizing, repairing, and anti-aging properties and can be applied to creams, lotions, and other cosmetics, thereby endowing these cosmetics with hydrating, moisturizing, sensitive skin repair, and anti-aging effects.

This invention belongs to the field of bioengineering and relates to glutamate oxidase mutants and their application in the biotransformation of α-ketoglutarate. The glutamate oxidase is derived from *Streptomyces molybdenum*, and a series of mutants were obtained through saturation mutation of its 536th amino acid residue. Among them, mutant C536E exhibits significantly enhanced enzyme activity. After expression, induction, and purification, the specific enzyme activity of the mutant is 2.06 U / mg, which is approximately 56% higher than that of wild-type glutamate oxidase. This invention also provides a method for constructing the glutamate oxidase mutant and its application in the preparation of α-ketoglutarate. Compared with existing technologies, the mutants provided by this invention have higher catalytic efficiency and show good application potential in the biotransformation of α-ketoglutarate.

The present application belongs to the field of biotechnology, and particularly relates to a kind of production alpha-ketoglutaric acid recombinant escherichia coli engineering strain and its construction method and application.The present application engineering strain A09 can realize high-efficiency catalysis to high-concentration L-glutamic acid sodium without adding any membrane breaker such as Triton X-100.Under the condition of high-intensity catalysis for 6 hours, the cell membrane structure of the bacterial cell is kept intact without obvious damage.This characteristic completely eliminates the problems such as cell toxicity, product purification complexity, cost increase and process safety reduction caused by the use of surfactant in traditional methods, realizes the perfect unity of "cell integrity" and "high catalytic efficiency", and provides an unprecedented technical solution for the large-scale, industrialized and low-cost production of alpha-ketoglutaric acid.

The application provides an application of alpha-ketoglutaric acid in improving corneal endothelial injury and dysfunction, and belongs to the technical field of biological medicine. The application finds that, as a key metabolic intermediate in the tricarboxylic acid cycle, alpha-ketoglutaric acid can significantly reduce corneal endothelial cell injury and dysfunction induced by various causes such as high glucose, genetic defects, high intraocular pressure and surgical trauma by improving mitochondrial energy metabolism, reducing oxidative stress, stabilizing mitochondrial structure and membrane potential. Experiments prove that alpha-ketoglutaric acid can be used in the form of local administration such as eye drops, anterior chamber perfusion, systemic oral administration or combined administration, effectively reduces corneal edema, reduces central corneal thickness, shortens the recovery time of corneal transparency, and has a clear protection and repair effect on diabetic-related corneal endothelial lesions, Fuchs corneal endothelial dystrophy, glaucoma high intraocular pressure injury and intraocular surgery-related endothelial injury.

The application discloses a mycotoxin attenuant for improving mitochondrial function and application, and has the following components: 10-20 parts by weight of L-malic acid, 3-5 parts by weight of alpha-ketoglutaric acid (salt), 15-25 parts by weight of itaconic acid and 1-3 parts by weight of 5-norwongenin. In mycotoxin contaminated feed, the addition of L-malic acid, alpha-ketoglutaric acid (salt), itaconic acid or 5-norwongenin alone cannot improve mitochondrial function or relieve mycotoxin toxicity. Compared with the combination of any one of the four components, the complete addition of the four components can significantly enhance mitochondrial oxidative phosphorylation, weaken glycolysis, obviously improve mitochondrial energy metabolism, effectively relieve mycotoxin-induced mitochondrial damage in the intestines and liver of livestock and poultry, and thus improve the production performance and health status of livestock and poultry. The application can significantly reduce the toxic effect of mycotoxin on livestock and poultry through the synergistic effect of the components.

This invention belongs to the field of biosensor technology, specifically relating to a fusion protein, a 2-ketoglutaric acid biosensor, and its applications. Specifically, this invention combines the MifS extracellular sensing domain MifS-SD of the MifS / MifR two-component signal transduction system in Pseudomonas aeruginosa PAO1 with a superfolded circular rearranged yellow fluorescent protein, successfully constructing a 2-ketoglutaric acid biosensor with a high response amplitude. Experiments demonstrate that this biosensor can achieve real-time, in-situ detection of 2-ketoglutaric acid in microorganisms and mammalian cells, and can support the detection of related enzyme activities and the screening of inhibitors in a highly efficient, low-cost, and high-throughput manner, thus possessing good practical application value.

The application belongs to the field of fine chemicals and medicinal chemistry, and particularly relates to a catalyst for Claisen ester condensation and a preparation method and application thereof. The application improves the preparation method of alpha-ketoglutarate calcium, adopts cheaper and more easily obtained raw materials, and innovatively invents a guanidino-amino co-functional KIT-6 mesoporous silica (Gua-NH2@KIT-6) to catalyze the Claisen ester condensation reaction. The catalyst carrier obtained by the application has a large pore size (4-12 nm), a high specific surface area (>600 m 2 / g), a surface rich in silicon hydroxyl groups (-SiOH), is convenient for grafting organic bases, has good thermal / chemical stability, is simple to handle, is safe to operate, reduces water consumption, is completely free of metal residues, is not dissolved, can be separated by filtration, can be reused after simple washing, has a wide substrate application range, and is suitable for industrialization.

The application belongs to the technical field of biomedical detection and electrochemical sensor, and relates to a preparation method and application of a glutamate-pyruvate transaminase biosensor. A soluble metal salt containing cobalt cyanide ions is added into deionized water; copper salt and a complexing agent are uniformly dispersed with deionized water, and after mixing, a complexing reaction is carried out, and then filtration is carried out; the obtained solid is washed and dried, and then is uniformly mixed with polyvinylpyrrolidone, centrifuged, calcined, and CuCo / C nanoparticles are obtained, which are fixed on a gold electrode to obtain a working electrode. Glutamate oxidase, L-alanine and alpha-ketoglutaric acid are uniformly mixed with chitosan to obtain an enzyme solution, and a glutamate-pyruvate transaminase sensor is obtained by dropwise addition. The glutamate-pyruvate transaminase biosensor prepared by the application has a wide linear range and good sensitivity.

This invention belongs to the field of biomedical technology, specifically relating to the application of α-ketoglutarate in the preparation of drugs that enhance the sensitivity of aquatic pathogens to florfenicol. This invention is the first to discover that α-ketoglutarate can significantly enhance the bactericidal effect of florfenicol against aquatic pathogens. Combined injection of α-ketoglutarate and florfenicol can reduce the number of bacteria in the liver and spleen of aquatic organisms, including fish, infected with aquatic pathogens, thus reducing damage to the organs and tissues of fish and other aquatic organisms and improving their survival rate. Therefore, α-ketoglutarate can be used as a synergist for florfenicol. Its combined application in the preparation of compound antibacterial agents can improve the efficacy of aquatic antibacterial drugs, significantly reduce the dosage of antibacterial drugs, and consequently reduce side effects and drug residues. This has significant application value and importance in the production and development of drugs against aquatic pathogens.

The application discloses a composition, a skin conditioner and application, and a cosmetic for skin conditioning, wherein the active ingredients include 0.02-600 parts by mass of a first active ingredient and 0.02-600 parts by mass of a second active ingredient; the first active ingredient includes tomato seeds and passion fruits in a mass ratio of (0.02-100):(0.1-500); and the second active ingredient includes a Pleurotus citrinopileatus and / or a substance containing alpha-ketoglutaric acid; the composition has excellent skin conditioning effects such as antioxidant, anti-inflammatory and anti-aging effects through synergistic effects of multiple active substances, effectively up-regulates and / or reverses the expression level of COL17A1 protein, resists damage to the skin caused by ultraviolet light and the like, and thus has comprehensive skin conditioning effects; meanwhile, the composition has natural components, high safety and excellent biocompatibility, has no obvious side effects, and has the advantages of clear activity, safety and reliability, and wide adaptability.

The present application belongs to the technical field of plant tissue culture, and particularly relates to a method for tissue culture and breeding of Amomum subulatum. The present application realizes large-scale factory production of Amomum subulatum by improving the synergistic effect of various factors such as a basic culture medium, exogenous plant hormones and exogenous alpha-ketoglutarate, so that the Amomum subulatum tissue culture seedlings maintain a suitable proliferation rate for a long time, and brownization occurs only after 21 generations of continuous transfer in the proliferation culture medium. In a relatively long production cycle, the Amomum subulatum tissue culture seedlings have a high proliferation rate, a low brownization rate, a weak degree of brownization, a high seedling proliferation rate and a high rooting rate, and the problem of brownization of the Amomum subulatum tissue culture seedlings is avoided.

This invention belongs to the field of genetic engineering technology, and specifically relates to a genetically engineered bacterium overexpressing phosphoenolacylcarboxylase and its application in the production of α-ketoglutarate. The method for constructing the genetically engineered bacterium of this invention includes: first, knocking out the pyruvate metabolism bypass gene, then knocking out the α-ketoglutarate metabolism bypass gene, and finally enhancing the expression of the ppc gene, thereby obtaining the genetically engineered bacterium. This genetically engineered bacterium can efficiently utilize glucose to produce α-ketoglutarate, greatly increasing the yield of α-ketoglutarate.

The application provides a tea oil raw material initial impurity removal and flavor preservation treatment method, and relates to the technical field of food processing. The steps comprise the following: S1, mixing alpha-ketoglutaric acid, amino acid and a eutectic solvent, homogenizing to obtain a treatment liquid; S2, mixing the tea oil raw material after color selection and pith removal with the treatment liquid, and separating and removing impurities by gradient pressure; S3, segmenting the tea oil raw material after impurity removal and heating by microwave, and immediately performing low-temperature treatment after the microwave heating is completed to obtain the tea oil raw material after impurity removal and flavor preservation; and S4, performing subsequent feeding, oil conveying and pressing. The application can not only remove impurities and preserve flavor, but also significantly increase the content of flavor substances by softening the treatment liquid, gradient impurity removal, microwave flavor extraction and cold nitrogen solidification. In addition, the application can improve the fluidity of the material, reduce the risk of material blockage in the later feeding process, improve the material integrity in the conveying process, improve the stability of subsequent pressing oil extraction, reduce the cost and energy consumption, prolong the equipment cleaning cycle, and has a good application prospect.

The application discloses a urea detection reagent, which comprises the following components: a buffer, reduced coenzyme I, alpha-ketoglutaric acid, ADP, urease, glutamate dehydrogenase, an excipient, a stabilizer, a surfactant and a preservative. The urea detection reagent has good thermal stability, is not prone to deterioration during storage, has a relatively wide effective testing range of urea, and can test a maximum concentration of urea of about 35 mmol / L.